Combined yeast-derived β-glucan with anti-tumor monoclonal antibody for cancer immunotherapy

Experimental and Molecular Pathology

Volumn 86, Issue 3, 2009, Pages 208-214

  Liu, Jingjing ^a   Gunn, Lacey ^a,b   Hansen, Richard ^a   Yan, Jun ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

glucan; Anti tumor monoclonal antibody; Complement; Complement regulatory proteins; Immunotherapy; Neutrophils

Indexed keywords

BETA GLUCAN; BEVACIZUMAB; CETUXIMAB; MONOCLONAL ANTIBODY; POLY (1,6) BETA DEXTRO GLUCOPYRANOSYL (1,3) BETA DEXTRO GLUCOPYRANOSE BETA GLUCAN; TRASTUZUMAB; UNCLASSIFIED DRUG; WHOLE GLUCAN PARTICLE BETA GLUCAN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EXPERIMENTAL MODEL; HUMAN; NEUTROPHIL; NONHUMAN; REVIEW; XENOGRAFT; YEAST;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BETA-GLUCANS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUTROPHILS; SACCHAROMYCES CEREVISIAE; SOLUBILITY; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA;

EID: 67349174213     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.01.006     Document Type: Review

References (74)

1. Adams G.P., et al. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
2. Allendorf D.J., et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and {beta}-glucan. J. Immunol. 174 (2005) 7050-7056
3. Ariizumi K., et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J. Biol. Chem. 275 (2000) 20157-20167
4. Baran J., et al. Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. Folia Histochem. Cytobiol. 45 (2007) 107-114
5. Bellamy W.T., et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59 (1999) 728-733
6. Bjorge L., et al. Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer 70 (1997) 14-25
7. Boscardin S.B., et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203 (2006) 599-606
8. Brown G.D., et al. Immune recognition. A new receptor for beta-glucans. Nature 413 (2001) 36-37
9. Brown G.D., et al. Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. 197 (2003) 1119-1124
10. Buettner R., et al. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol. Cancer Res. 5 (2007) 823-832
11. Cheung N.K., et al. Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 8 (2002) 1217-1223
12. Cheung N.K., et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 51 (2002) 557-564
13. Cramer D.E., et al. {Beta}-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 107 (2006) 835-840
14. Cramer D.E., et al. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 26 (2008) 1231-1240
15. Davis I.D., et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7 (2007) 13
16. Decaussin M., et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol. 188 (1999) 369-377
17. Di Carlo E., et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97 (2001) 339-345
18. Di Gaetano N., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114 (2001) 800-809
19. Diamond M.S., et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J. Cell. Biol. 130 (1995) 1473-1482
20. Diamond M.S., et al. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell. Biol. 120 (1993) 1031-1043
21. Donev R.M., et al. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res. 66 (2006) 2451-2458
22. Dutta T., et al. Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J. Neurooncol. 64 (2003) 31-44
23. Ensley H.E., et al. NMR spectral analysis of a water-insoluble (1->3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. 258 (1994) 307-311
24. Ferrer F.A., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54 (1999) 567-572
25. Fishelson Z., et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40 (2003) 109-123
26. Foon K.A., et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. 96 (1995) 334-342
27. Gantner B.N., et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197 (2003) 1107-1117
28. Gawronski M., et al. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle x-ray scattering. Biopolymers 50 (1999) 569-578
29. Gelderman K.A., et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25 (2004) 158-164
30. Hinton P.R., et al. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279 (2004) 6213-6216
31. Hinton P.R., et al. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176 (2006) 346-356
32. Hong F., et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63 (2003) 9023-9031
33. Hong F., et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173 (2004) 797-806
34. Horner H., et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J. Immunol. 179 (2007) 337-345
35. Johnson P., et al. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30 (2003) 3-8
36. Karanikas V., et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100 (1997) 2783-2792
37. Ko E.C., et al. Immunotherapy of malignant diseases. Challenges and strategies. Int. Arch. Allergy Immunol. 132 (2003) 294-309
38. Koga Y., et al. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 64 (2004) 1037-1043
39. Kushner B.H., et al. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res. 51 (1991) 4865-4870
40. Lavigne L.M., et al. Beta-glucan is a fungal determinant for adhesion-dependent human neutrophil functions. J. Immunol. 177 (2006) 8667-8675
41. LeibundGut-Landmann S., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8 (2007) 630-638
42. Li B., et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J. Immunol. 177 (2006) 1661-1669
43. Li B., et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res. 67 (2007) 7421-7430
44. Li B., et al. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin. Immunol. 124 (2007) 170-181
45. Li B., et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 68 (2008) 2400-2408
46. Loberg R.D., et al. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8 (2006) 69-78
47. Macor P., et al. Complement as effector system in cancer immunotherapy. Immunol. Lett. 111 (2007) 6-13
48. Meng R., et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin. Cancer Res. 10 (2004) 1274-1281
49. Modak S., et al. Rituximab therapy of lymphoma is enhanced by orally administered (1->3),(1->4)-D-beta-glucan. Leuk. Res. 29 (2005) 679-683
50. Nakayama H., et al. Lyn-coupled LacCer-enriched lipid rafts are required for CD11b/CD18-mediated neutrophil phagocytosis of nonopsonized microorganisms. J. Leukoc. Biol. 83 (2008) 728-741
51. Nicholson S., et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. 53 (2004) 809-816
52. Nisini R., et al. Beta-glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J. Leukoc. Biol. 82 (2007) 1136-1142
53. Patchen M.L., et al. Mobilization of peripheral blood progenitor cells by Betafectin PGG-glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells 16 (1998) 208-217
54. Patchen M.L., et al. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp. Hematol. 26 (1998) 1247-1254
55. Price D.J., et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 12 (2001) 129-135
56. Ross G.D. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol. 20 (2000) 197-222
57. Ross G.D., et al. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement 4 (1987) 61-74
58. Saijo S., et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol. 8 (2007) 39-46
59. Salvador C., et al. Yeast-derived {beta}-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin. Cancer Res. 14 (2008) 1239-1247
60. Senter P.D., et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49 (1989) 5789-5792
61. Sobrero A.F., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 2311-2319
62. Spiridon C.I., et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8 (2002) 1720-1730
63. Stein R., et al. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Clin. Cancer Res. 11 (2005) 2727-2734
64. Taylor P.R., et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat. Immunol. 8 (2007) 31-38
65. Thornton B.P., et al. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156 (1996) 1235-1246
66. Vetvicka V., et al. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98 (1996) 50-61
67. Wasser S.P., et al. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol. 19 (1999) 65-96
68. Williams D.L., et al. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 22 (1991) 139-155
69. Xia Y., et al. Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol. 162 (1999) 7285-7293
70. Yakubenko V.P., et al. A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity. J. Biol. Chem. 277 (2002) 48635-48642
71. Yan J., et al. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin. Biol. Ther. 5 (2005) 691-702
72. Yan J., et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163 (1999) 3045-3052
73. Yan J., et al. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology 46 (2000) 39-54
74. Zhang H., et al. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol. Ther. 2 (2003) S122-126